
[nature](#) > [nature reviews clinical oncology](#) > [comment](#) > article

Comment | Published: 12 September 2024

Vorasicidenib: a new hope or a false promise for patients with low-grade glioma?

[Stanislav Lazarev](#)  & [Kunal K. Sindhu](#)

Nature Reviews Clinical Oncology (2024)

663 Accesses | 33 Altmetric | [Metrics](#)

Despite recent FDA approval, the clinical utility of vorasicidenib in the treatment of IDH-mutant low-grade gliomas remains unclear. Herein, we critique the pivotal trial of vorasicidenib, and highlight the questionable choice of control intervention and end points, ethical concerns, as well as the uncertain efficacy observed, and argue that the approval might be premature given the high cost of this drug and lack of clear benefit over standard treatments.

This is a preview of subscription content, [access via your institution](#)

References

1. FDA approves vorasicidenib for grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. News release. *FDA*, <https://tinyurl.com/3jv48wa9> (6 August 2024).
 2. National Comprehensive Cancer Network. *NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 2.2024* (25 July 2024).
 3. Mellinghoff, I. K. et al. Vorasicidenib in IDH1- or IDH2-mutant low-grade glioma. *N. Engl. J. Med.* **389**, 589–601 (2023).
-

4. Buckner, J. C. et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. *N. Engl. J. Med.* **374**, 1344–1355 (2016).

5. van den Bent, M. J. et al. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. *Lancet Oncol* **22**, 813–823 (2021).

6. Guillevin, R., Herpe, G., Verdier, M. & Guillevin, C. Low-grade gliomas: the challenges of imaging. *Diagn. Interv. Imaging* **95**, 957–963 (2014).

7. National Institutes of Health. Basics of clinical research and trials. *National Institutes of Health* <https://www.nih.gov/health-information/nih-clinical-research-trials-you/basics> (accessed 10 August 2024).

8. Iwamoto, F. et al. CTNI-16. NRG-RTOG 9802 observation arm – long term result. *Neuro-oncol* **24** (Suppl. 7), vii73 (2022).

9. Pertz, M. et al. Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up. *J. Neurooncol.* **164**, 353–366 (2023).

10. Servier Pharmaceuticals' vorasidenib receives FDA approval for glioma. *MedCity News* <https://medcitynews.com/2024/08/brain-cancer-glioma-fda-approval-servier-pharmaceuticals-vorasidenib-voranigo/> (8 August 2024).

Author information

Authors and Affiliations

Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Stanislav Lazarev & Kunal K. Sindhu

Corresponding author

Correspondence to [Stanislav Lazarev](#).

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

[Reprints and permissions](#)

About this article

Cite this article

Lazarev, S., Sindhu, K.K. Vorasidenib: a new hope or a false promise for patients with low-grade glioma?. *Nat Rev Clin Oncol* (2024). <https://doi.org/10.1038/s41571-024-00944-5>

Published

12 September 2024

DOI

<https://doi.org/10.1038/s41571-024-00944-5>

Subjects [CNS cancer](#) • [Targeted therapies](#)

Nature Reviews Clinical Oncology (*Nat Rev Clin Oncol*) | ISSN 1759-4782 (online) | ISSN 1759-4774 (print)